A Phase 1/2, Randomized, Stratified, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1010 Seasonal Influenza Vaccine in Healthy Adults 18 Years and Older
Latest Information Update: 29 Apr 2024
At a glance
- Drugs MRNA-1010 (Primary)
- Indications Influenza virus infections
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Moderna Therapeutics
- 25 Apr 2024 According to a Moderna media release, data from this trial will be presented at the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Global Congress in Barcelona, Spain, from April 27-30, 2024.
- 24 May 2023 Interim Results, safety and reactogenicity of mRNA-1010 or an active comparator (standard-dose influenza vaccine) and humoral immunogenicity at 28 days after vaccination, presented at the 119th International Conference of the American Thoracic Society
- 19 Nov 2022 Status changed from active, no longer recruiting to completed.